CG Oncology Undervalued Going Into A Busy 2026
Source: SeekingAlpha
2025-12-23 04:43:51 ET
Biotech stocks may generally be data-driven, but that doesn’t mean that the share prices always reflect the value that the data imply. Such is the case with CG Oncology, Inc. ( CGON ), where the company’s data releases since my last update on the company have only strengthened the case for the company’s sole drug cretostimogene grenadenorepvec (“creto”), an oncolytic adenovirus in development for bladder cancer....
Read the full article on Seeking Alpha
For further details see:
CG Oncology Undervalued Going Into A Busy 2026
CG Oncology, Inc.
NASDAQ: CGON
CGON Trading
4.15% G/L:
$65.90 Last:
272,869 Volume:
$64.67 Open:
CGON Latest News
March 21, 2026 06:25:08 pm
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
February 27, 2026 08:30:00 am
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
February 23, 2026 08:00:00 am
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
CGON Stock Data
$4,282,567,443
74,696,882
0.15%
55
N/A
Biotechnology & Life Sciences
Healthcare
US
Irvine
